# Becton Dickinson (BDX) Q3 FY2026 earnings

Results filed 2026-08-06 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/bdx/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/10795/000162828026053790/0001628280-26-053790-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

BD's first full quarter as a focused MedTech company showed broad growth across all four segments, led by BioPharma Systems' GLP-1 injection pen collaboration in Brazil and Interventional's new laser launch.

BD completed its separation of the Biosciences and Diagnostic Solutions business into Waters in February, and this was its first full quarter as 'New BD' with four segments. All four grew. Advanced Patient Monitoring was the fastest-growing unit, and U.S. sales outpaced international. Product news included a Vizient Innovative Technology contract for the CentroVena One insertion system, the Elyra Thulium Fiber Laser System for kidney stone care, and an EMS semaglutide launch in Brazil on BD's Vystra Injection Pen.
Management is steering toward a simpler, more focused company built around key growth platforms, under its 'Excellence Unleashed' strategy. It has exited operational activities and projects that no longer fit, taking $450 million of non-cash impairment charges over nine months. The main risks are the Alaris infusion system's timing for return to market in the U.S., tariffs, Middle East supply disruption, and changes in U.S. vaccine and pharmaceutical policy that could reduce demand.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $4,983 | up 5.4% reported, 4.4% FXN | GAAP |
| Diluted EPS from continuing operations | $1.64 | up 4.5% from a year ago | GAAP |
| Adjusted diluted EPS from continuing operations | $3.23 | up 4.9% from a year ago | non-GAAP |
| Net income from continuing operations | $451 | flat (up 0.1%) from a year ago | GAAP |
| Operating income | 663 | down 10.3% from a year ago | GAAP |
| Nine-month cash from continuing operations | $2.1 billion | up 33.3% year to date | GAAP |
| Nine-month free cash flow | $1.7 billion | up 44.6% year to date | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Medical Essentials | $1,675 | up 4.5% reported, 3.2% FXN |
| Connected Care | $1,224 | up 4.9% reported, 4.4% FXN |
| BioPharma Systems | $670 | up 6.6% reported, 5.2% FXN |
| Interventional | $1,414 | up 6.4% reported, 5.5% FXN |
| Advanced Patient Monitoring | $309 | up 10.9% reported, 11.2% FXN |
| Specimen Management | $511 | up 8.7% reported, 7.0% FXN |
| Peripheral Intervention | $552 | up 7.8% reported, 6.1% FXN |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Adjusted diluted EPS | fiscal 2026 | $12.62 to $12.72 |

## Key takeaways

1. **First full quarter as focused 'New BD'** Following the February spin-off and combination with Waters, BD operates four segments and said the quarter showed early benefits of a more focused MedTech company. All four segments grew.
2. **BioPharma Systems tied to GLP-1 self-injection** BD announced a collaboration with EMS, a leading Brazilian pharmaceutical company, to launch semaglutide using BD's Vystra Injection Pen platform. It extends BD's role in access to obesity and type 2 diabetes therapies.
3. **Interventional expanded kidney stone portfolio** BD launched the Elyra Thulium Fiber Laser System, designed to improve efficiency, versatility and workflow for urology teams. Interventional also grew 6.4% as reported.
4. **Vizient award validates CentroVena One** The BD CentroVena One Insertion System won a Vizient Innovative Technology contract. BD describes it as designed to simplify central line insertion and improve patient and clinician safety.
5. **Portfolio pruning under Excellence Unleashed** BD recorded $450 million of non-cash impairments to exit activities and projects no longer aligned with its strategy. The goal is simpler operations and resources behind its most value-creating platforms.

## Questions

**What did BD launch or announce in Q3 FY2026?** BD launched the Elyra Thulium Fiber Laser System for kidney stone care, won a Vizient Innovative Technology contract for CentroVena One, and announced an EMS collaboration for a semaglutide launch in Brazil using the Vystra Injection Pen platform.
**What is BD's strategy after the Waters transaction?** BD, now called New BD, is a more focused MedTech company with four segments, concentrating on key growth platforms, innovation and BD Excellence under its Excellence Unleashed strategy.
**Which BD businesses grew fastest this quarter?** Advanced Patient Monitoring grew 10.9% reported and Specimen Management 8.7%. Among segments, BioPharma Systems rose 6.6% and Interventional 6.4%.
**How is BD participating in the GLP-1 market?** Through a collaboration with EMS in Brazil, whose semaglutide launch will use BD's Vystra Injection Pen platform for self-injection by patients with obesity and type 2 diabetes.
**What are the main risks BD flags for its plan?** BD cites tariffs, Middle East supply chain disruption, U.S. policy changes affecting vaccines and pharmaceuticals, and the timing of the Alaris infusion system's return to market in the U.S.

